Expression and characterization of wild type and mutant recombinant human sulfamidase - Implications for Sanfilippo (mucopolysaccharidosis IIIA) syndrome

被引:33
|
作者
Perkins, KJ [1 ]
Byers, S [1 ]
Yogalingam, G [1 ]
Weber, B [1 ]
Hopwood, JJ [1 ]
机构
[1] Womens & Childrens Hosp, Dept Chem Pathol, Lysosomal Disorders Res Unit, N Adelaide, SA 5006, Australia
关键词
D O I
10.1074/jbc.274.52.37193
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mucopolysaccharidosis IIIA (MPS-IIIA) is an autosomal recessive lysosomal storage disorder caused by the deficiency of sulfamidase (NS; EC 3.10.1.1), resulting in defective degradation and storage of heparan sulfate. This paper reports the production and characterization of monoclonal and polyclonal antibodies against recombinant human sulfamidase (rhNS) to quantitate and characterize normal and mutant sulfamidase produced from the wild type NS expression vector. Glycosylation and phosphorylation studies of immunoprecipitated rhNS show that all five potential glycosylation sites are utilized, with three high mannose/hybrid oligosaccharides and two simpler chains, with at least one functional mannose B-phosphate group. An NS quantification system was developed to determine the effect of the three most common and severe patient mutations: S66W (Italy), R74C (Poland), and R245H (The Netherlands), The quantity and specific activity of expressed mutant rhNS was significantly lower than expressed normal rhNS, with 0.3, 0.2, and 0.05% of normal rhNS produced and 15, 17, and 83% of normal specific activity for S66W, R74C, and R245H observed, respectively. The recent structural elucidation of N-acetylgalactosamine-4-sulfatase was utilized to postulate the effect on the structure-function relationship of NS, The characterization of normal and mutated rhNS has relevance for efficient diagnosis and therapeutic developments for MPS-IIIA patients.
引用
收藏
页码:37193 / 37199
页数:7
相关论文
共 50 条
  • [31] Updated Results of Transpher A, a Multicenter, Single-Dose, Phase 1/2 Clinical Trial of ABO-102 Gene Therapy for Sanfilippo Syndrome Type A (Mucopolysaccharidosis IIIA)
    Flanigan, Kevin M.
    Smith, Nicholas J. C.
    Couce, Maria L.
    Escolar, Maria
    Truxal, Kristen V.
    McBride, Kim L.
    de Castro, Maria J.
    Fuller, Maria
    Paneda, Astrid
    Ruiz, Juan
    MOLECULAR THERAPY, 2021, 29 (04) : 104 - 105
  • [32] HUMAN CYTOPLASMIC 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A SYNTHASE - EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF RECOMBINANT WILD-TYPE AND CYS(129) MUTANT ENZYMES
    ROKOSZ, LL
    BOULTON, DA
    BUTKIEWICZ, EA
    SANYAL, G
    CUETO, MA
    LACHANCE, PA
    HERMES, JD
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1994, 312 (01) : 1 - 13
  • [33] EXPRESSION AND CHARACTERIZATION OF WILD-TYPE AND MUTANT HUMAN LAMIN-B IN THE BACULOVIRUS-INSECT CELL SYSTEM
    GOSS, VL
    STRATTON, CA
    HOCEVAR, BA
    BURNS, DJ
    FIELDS, AP
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 82 - 82
  • [34] Interim results of Transpher A, a multicentre, single-dose, phase 1/2 clinical trial of ABO-102 investigational gene therapy for Sanfilippo syndrome type A (mucopolysaccharidosis IIIA)
    Flanigan, Kevin M.
    Smith, Nicholas J. N.
    Couce, Maria L.
    Escolar, Maria
    Truxal, Kristen V.
    McBride, Kim L.
    de Castro, Maria J.
    Fuller, Maria
    Paneda, A.
    Ruiz, J.
    del Campo, A. B.
    Grachev, I.
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S43 - S43
  • [35] Comparison of binding and functional characteristics of wild type and mutant recombinant human gastrin releasing peptide receptor
    Pullen, M
    Kumar, J
    Wu, HL
    Dytko, G
    Nambi, P
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R650 - R650
  • [36] Updated results of Transpher A, a multicenter, single-dose, Phase 1/2 clinical trial of ABO-102 investigational gene therapy for Sanfilippo syndrome type A (mucopolysaccharidosis IIIA)
    Flanigan, K. M.
    Smith, N. J. C.
    Couce, M. L.
    Escolar, M.
    Truxal, K. V.
    McBride, K. L.
    de Castro, M. J.
    Fuller, M.
    Paneda, A.
    Ruiz, J.
    del Campo, A. B.
    Grachev, I. D.
    NEUROLOGY, 2022, 98 (18)
  • [37] PURIFICATION AND CHARACTERIZATION OF WILD-TYPE AND TS112 MUTANT PROTEIN-IIIA OF HUMAN ADENOVIRUS-2 EXPRESSED IN ESCHERICHIA-COLI
    CUILLEL, M
    CORTOLEZZIS, B
    CHROBOCZEK, J
    LANGOWSKI, J
    RUIGROK, RWH
    JACROT, B
    VIROLOGY, 1990, 175 (01) : 222 - 231
  • [38] Expression, purification and kinetic characterization of wild-type human ornithine transcarbamylase and a recurrent mutant that produces 'late onset' hyperammonaemia
    Morizono, H
    Tuchman, M
    Rajagopal, BS
    McCann, MT
    Listrom, CD
    Yuan, XL
    Venugopal, D
    Barany, G
    Allewell, NM
    BIOCHEMICAL JOURNAL, 1997, 322 : 625 - 631
  • [39] Protein expression, characterization and activity comparisons of wild type and mutant DUSP5 proteins
    Nayak, Jaladhi
    Gastonguay, Adam J.
    Talipov, Marat R.
    Vakeel, Padmanabhan
    Span, Elise A.
    Kalous, Kelsey S.
    Kutty, Raman G.
    Jensen, Davin R.
    Pokkuluri, Phani Raj
    Sem, Daniel S.
    Rathore, Rajendra
    Ramchandran, Ramani
    BMC BIOCHEMISTRY, 2014, 15
  • [40] Toll-like receptor activation profiles of wild-type, recombinant, and mutant Lactobacillus: implications for vaccine design
    Stoeker, L.
    Nordone, S.
    LaVoy, A.
    Tallon, R.
    Klaenhammer, T.
    Dean, G.
    RETROVIROLOGY, 2009, 6